Compare AIBZ & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIBZ | IVVD |
|---|---|---|
| Founded | N/A | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.0M | 212.6M |
| IPO Year | 2026 | 2021 |
| Metric | AIBZ | IVVD |
|---|---|---|
| Price | $2.66 | $0.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 1.0M | ★ 3.4M |
| Earning Date | 11-27-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | N/A | $12.40 |
| Revenue Next Year | N/A | $44.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $2.22 | $0.53 |
| 52 Week High | $9.91 | $3.07 |
| Indicator | AIBZ | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 40.68 |
| Support Level | $2.24 | $0.53 |
| Resistance Level | $3.85 | $0.66 |
| Average True Range (ATR) | 0.40 | 0.05 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 25.16 | 25.85 |
Bitzero Holdings Inc is a provider of IT energy infrastructure and high-efficiency power for data centers. It focuses on data center development, Bitcoin mining, and obtaining strategic data center hosting partnerships. The company has four data center locations in the North American and Scandinavian regions, powered by clean, low-carbon energy sources. The company is driven by experience in infrastructure and a passion for positive change to become the international leader in Blockchain mining and HPC hosting in a sustainable fashion that emphasizes the long-term value proposition for all stakeholders.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.